Navigation Links
LIQUENT Announces XEVMPD Educational Series and Data Assessment Tool
Date:1/10/2012

HORSHAM, Pa., Jan. 10, 2012 /PRNewswire/ -- LIQUENT, Inc. the global leader in regulatory information management solutions and services, is pleased to announce LIQUENT's XEVMPD Educational Series and Data Assessment tool. Both are designed to assist in complying with the July 2012 deadline for submitting product information in eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) format. 

LIQUENT's XEVMPD Educational Series is designed to educate internal personnel about the requirements for XEVMPD.  The sessions consist of five recorded modules, for a total of four hours of training, focused on areas such as the understanding of why EMA is requiring XEVMPD, recent announcements and timelines, and requirements for authorized products, approved substances, and development substances and products. 

The XEVMPD Data Assessment tool will assist organizations in determining what data is needed for compliance and where the data is currently managed or tracked within the organization. 

"Companies are facing an unprecedented timeline for compliance," said Sarah Powell, Executive Director of Regulatory Affairs and Writing Services. "The LIQUENT XEVMPD Educational Series and XEVMPD Data Assessment tool provide an opportunity for companies to get a jump start on preparing their organizations, by ensuring employees are educated about the requirements and providing a clear understanding of the data needs." 

Successful transition to comply with the new XEVMPD requirements will mandate companies to evaluate standards, processes, technology, and organizational needs. LIQUENT's educational and solution offerings will support companies as they make necessary assessments.

For more information, Please contact info@liquent.com.

About LIQUENT, Inc.

LIQUENT provides technology and outsourcing solutions focused around regulatory submission preparation and tasks, dossier planning, eCTD to CTD publishing and registration tracking capabilities.  LIQUENT is the premier provider of a scalable, regulatory information management platform and associated regulatory & clinical services that can be leveraged throughout a client organization.

Contact:
Julie Burgess
Manager, Strategic Marketing
215-328-4513
Julie.burgess@liquent.com

 

 


'/>"/>
SOURCE LIQUENT, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Omnicare Clinical Research Licenses LiquentConnect to Create Added Value for Clients
2. BNA Books Announces the Publication of the 2011 Cumulative Supplement to "Pharmaceutical Law: Regulation of Research, Development, and Marketing"
3. NewCardio Announces Changes in Board of Directors and Executive Management
4. RSB Spine, LLC, Announces United States Patent Allowance
5. Hill-Rom Announces Preliminary Fiscal First Quarter Financial Results; Updates 2012 Financial Outlook
6. SequelMed Announces ANSI 5010 Upgrade for Its Users
7. Fembody™ Nutrition Announces Paula Abdul as Spokeswoman
8. ShangPharma Announces Opening of New Facility to Support Lillys Pipeline
9. Elsevier Announces Two Tetrahedron Symposia for 2012
10. Volcano Corporation Announces Preliminary Fourth Quarter 2011 Revenues
11. Hanger Orthopedic Group, Inc. Announces Fourth Quarter 2011 Earnings Release Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , Dec. 5, 2016 ... hydroxyurea (HU) in Complete Hematologic Response (CHR) ... ropeginterferon alfa-2b versus HU AOP will submit ... CONTINUATION-PV to obtain European marketing authorization in the coming months ... the FDA as it seeks approval for commercialization in the ...
(Date:12/4/2016)... 2016 Sickle cell disease (SCD) is an ... cells that get stuck in veins and block blood ... and complications leading to death. Each year, approximately 300,000 ... most of them lack access to comprehensive care or ... therapy for SCD, a pill called hydroxyurea approved more ...
(Date:12/2/2016)... SILVER SPRING, Md. , Dec. 2, 2016 /PRNewswire-USNewswire/ ... a new indication for Jardiance (empagliflozin) to reduce the ... 2 diabetes mellitus and cardiovascular disease. ... adults with type 2 diabetes mellitus," said Jean-Marc ... Metabolism and Endocrinology Products in FDA,s Center for Drug ...
Breaking Medicine Technology:
(Date:12/4/2016)... , ... December 04, 2016 , ... ... major cosmetic surgery can now take advantage of a cosmetic procedure known as ... rejuvenation treatment that reduces the appearance of age spots, fine lines, uneven ...
(Date:12/4/2016)... ... December 04, 2016 , ... Responsible dental care hinges ... brush properly to achieve optimal results. This important necessity inspired an inventor from Las ... a way to ensure that people break or avoid bad techniques of brushing the ...
(Date:12/2/2016)... ... ... Lori G. Cohen and Sara K. Thompson , shareholders in global ... Institute’s 21st Drug & Medical Device Litigation Conference , taking place in New York ... who chairs the firm’s Pharmaceutical, Medical Device & Health Care Litigation Practice and the ...
(Date:12/2/2016)... ... December 02, 2016 , ... On Dec. 2, 2016, CURE® magazine will host ... honoring the 2016 MPN Heroes—eight individuals who have made a difference in the field ... the standard of care, demonstrating leadership within the MPN community and/or a commitment to ...
(Date:12/2/2016)... Dothan, AL (PRWEB) , ... December 02, 2016 ... ... leaders from across the Dothan-Wiregrass Area in Alabama are expected to attend the ... Mike Schmitz, will help provide scholarship funds for area students and operating support ...
Breaking Medicine News(10 mins):